Retatrutide's evidence base runs from Phase 2 results published in the New England Journal of Medicine in 2023 (dose-dependent weight reductions near 24%, HbA1c improvements, documented energy-expenditure increases) to Phase 3 TRIUMPH readouts in 20252026, including TRIUMPH-1's ~28% mean reduction at the 12 mg dose
Large-scale randomised controlled trials and post-marketing surveillance data have not identified ED as a common or characteristic adverse effect of these medications
Slow Down Stomach Emptying : Semaglutide slows down the time it takes for food to move from the stomach into the small intestine
An increased heart rate means the heart is working harder than usual, which can sometimes lead to chest pain, especially in people with underlying heart conditions
doi: 10.1128/AEM.68.4.1561-1568.2002 110 ValeF
These injections can be used on specific areas of the body, including the face and body, to improve contour and reduce unwanted fat
